Medulloblastoma molecular dissection: the way toward targeted therapy - PubMed
- ️Invalid Date
Review
Medulloblastoma molecular dissection: the way toward targeted therapy
Marc Remke et al. Curr Opin Oncol. 2013 Nov.
Abstract
Purpose of review: The advent of integrated genomics revealed profound insights into medulloblastoma pathogenesis. However, these biological findings have yet to be translated into the clinic, as current treatment comprises surgical resection, conventional irradiation, and chemotherapy resulting in significant long-term sequelae. We sought to highlight the potential areas for targeted therapy based on our new understanding of the subgroup-specific tumor biology.
Recent findings: Recently, four distinct molecular subgroups of medulloblastoma have been identified [WNT (wingless), SHH (sonic hedgehog), Group 3, and Group 4]. Profiling of these subgroups revealed distinct genomic events, several of which represent actionable targets for therapy. Specifically, stratification of patients into their respective subgroups has profound prognostic impact, wherein therapy can be de-escalated in patients with favorable prognosis, and intensified therapy or novel agents can be considered in patients with poor prognosis. Novel subgroup-specific therapies are being explored in clinical trials, particularly for the SHH subgroup. Epigenetic modifiers are also recurrently affected in medulloblastoma suggesting that epigenetic therapy can be considered in a subset of patients.
Summary: The identification of subgroup-specific, actionable therapeutic targets has the potential to revolutionize therapy for medulloblastoma patients, and result in significantly improved quality of life in survivors and improved overall survival.
Similar articles
-
Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma.
Park AK, Lee JY, Cheong H, Ramaswamy V, Park SH, Kool M, Phi JH, Choi SA, Cavalli F, Taylor MD, Kim SK. Park AK, et al. BMC Cancer. 2019 Jun 11;19(1):571. doi: 10.1186/s12885-019-5742-x. BMC Cancer. 2019. PMID: 31185958 Free PMC article.
-
FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma.
Remke M, Hielscher T, Korshunov A, Northcott PA, Bender S, Kool M, Westermann F, Benner A, Cin H, Ryzhova M, Sturm D, Witt H, Haag D, Toedt G, Wittmann A, Schöttler A, von Bueren AO, von Deimling A, Rutkowski S, Scheurlen W, Kulozik AE, Taylor MD, Lichter P, Pfister SM. Remke M, et al. J Clin Oncol. 2011 Oct 10;29(29):3852-61. doi: 10.1200/JCO.2011.36.2798. Epub 2011 Sep 12. J Clin Oncol. 2011. PMID: 21911727
-
Ramaswamy V, Northcott PA, Taylor MD. Ramaswamy V, et al. Cancer Genet. 2011 Nov;204(11):577-88. doi: 10.1016/j.cancergen.2011.11.001. Cancer Genet. 2011. PMID: 22200083 Review.
-
Rapid diagnosis of medulloblastoma molecular subgroups.
Schwalbe EC, Lindsey JC, Straughton D, Hogg TL, Cole M, Megahed H, Ryan SL, Lusher ME, Taylor MD, Gilbertson RJ, Ellison DW, Bailey S, Clifford SC. Schwalbe EC, et al. Clin Cancer Res. 2011 Apr 1;17(7):1883-94. doi: 10.1158/1078-0432.CCR-10-2210. Epub 2011 Feb 16. Clin Cancer Res. 2011. PMID: 21325292 Free PMC article.
-
Medulloblastomas in adults: prognostic factors and lessons from paediatrics.
Fellay CN, Frappaz D, Sunyach MP, Franceschi E, Brandes AA, Stupp R. Fellay CN, et al. Curr Opin Neurol. 2011 Dec;24(6):626-32. doi: 10.1097/WCO.0b013e32834cd4b1. Curr Opin Neurol. 2011. PMID: 22027544 Review.
Cited by
-
NRP1 inhibition modulates radiosensitivity of medulloblastoma by targeting cancer stem cells.
Douyère M, Gong C, Richard M, Pellegrini-Moïse N, Daouk J, Pierson J, Chastagner P, Boura C. Douyère M, et al. Cancer Cell Int. 2022 Dec 1;22(1):377. doi: 10.1186/s12935-022-02796-4. Cancer Cell Int. 2022. PMID: 36457009 Free PMC article.
-
Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma.
Park AK, Lee JY, Cheong H, Ramaswamy V, Park SH, Kool M, Phi JH, Choi SA, Cavalli F, Taylor MD, Kim SK. Park AK, et al. BMC Cancer. 2019 Jun 11;19(1):571. doi: 10.1186/s12885-019-5742-x. BMC Cancer. 2019. PMID: 31185958 Free PMC article.
-
Lukoseviciute M, Theodosopoulou A, Holzhauser S, Dalianis T, Kostopoulou ON. Lukoseviciute M, et al. Oncol Rep. 2023 Jun;49(6):125. doi: 10.3892/or.2023.8562. Epub 2023 May 5. Oncol Rep. 2023. PMID: 37144508 Free PMC article.
-
Mastronuzzi A, Miele E, Po A, Antonelli M, Buttarelli FR, Colafati GS, del Bufalo F, Faedda R, Spinelli GP, Carai A, Giangaspero F, Gulino A, Locatelli F, Ferretti E. Mastronuzzi A, et al. BMC Cancer. 2014 Apr 16;14:262. doi: 10.1186/1471-2407-14-262. BMC Cancer. 2014. PMID: 24739212 Free PMC article.
-
Li J, Zhao S, Lee M, Yin Y, Li J, Zhou Y, Ballester LY, Esquenazi Y, Dashwood RH, Davies PJA, Parsons DW, Li XN, Huang Y, Sun D. Li J, et al. Sci Adv. 2020 Oct 16;6(42):eabb5427. doi: 10.1126/sciadv.abb5427. Print 2020 Oct. Sci Adv. 2020. PMID: 33067228 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials